Cargando…
Efficacy of Modified Treat-and-Extend Regimen of Aflibercept for Macular Edema from Branch Retinal Vein Occlusion: 2-Year Prospective Study Outcomes
This study aimed to evaluate the long-term (24-month) efficacy and safety of a modified treat-and-extend (mTAE) regimen of aflibercept for macular edema (ME) due to branch retinal vein occlusion (BRVO). This was a prospective multicenter intervention study. We evaluated 50 eyes in 50 patients with M...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307685/ https://www.ncbi.nlm.nih.gov/pubmed/34300328 http://dx.doi.org/10.3390/jcm10143162 |
_version_ | 1783728106496851968 |
---|---|
author | Arai, Yusuke Takahashi, Hidenori Inoda, Satoru Sakamoto, Shinichi Tan, Xue Inoue, Yuji Tominaga, Satoko Kawashima, Hidetoshi Yanagi, Yasuo |
author_facet | Arai, Yusuke Takahashi, Hidenori Inoda, Satoru Sakamoto, Shinichi Tan, Xue Inoue, Yuji Tominaga, Satoko Kawashima, Hidetoshi Yanagi, Yasuo |
author_sort | Arai, Yusuke |
collection | PubMed |
description | This study aimed to evaluate the long-term (24-month) efficacy and safety of a modified treat-and-extend (mTAE) regimen of aflibercept for macular edema (ME) due to branch retinal vein occlusion (BRVO). This was a prospective multicenter intervention study. We evaluated 50 eyes in 50 patients with ME due to BRVO enrolled between October 2016 and September 2017. The patients received intravitreal aflibercept (IVA) injections according to a mTAE regimen for 24 months. This study reports the secondary endpoints of best-corrected visual acuity (BCVA) and central subfield thickness (CST) at 24 months and compares them with previously reported primary endpoints. Compared with baseline BCVA and CST of 0.33 (0.27) and 488 (165) µm (mean (standard deviation)), respectively, BCVA and CST were significantly improved at 12 and 24 months (12 months: 0.059 (0.19) LogMAR and 299 (112) µm; 24 months: 0.034 (0.18) LogMAR and 272 (81) µm, respectively; both p < 0.0001). Over the 24-month period, the mean number of IVA injections and clinic visits was 7.4 (3.3) and 11.1 (2.0), respectively. The mTAE regimen of IVA injections for ME due to BRVO was effective for improving BCVA and reducing CST over 24 months. This regimen shows promise for reducing the number of injections and clinic visits. |
format | Online Article Text |
id | pubmed-8307685 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83076852021-07-25 Efficacy of Modified Treat-and-Extend Regimen of Aflibercept for Macular Edema from Branch Retinal Vein Occlusion: 2-Year Prospective Study Outcomes Arai, Yusuke Takahashi, Hidenori Inoda, Satoru Sakamoto, Shinichi Tan, Xue Inoue, Yuji Tominaga, Satoko Kawashima, Hidetoshi Yanagi, Yasuo J Clin Med Article This study aimed to evaluate the long-term (24-month) efficacy and safety of a modified treat-and-extend (mTAE) regimen of aflibercept for macular edema (ME) due to branch retinal vein occlusion (BRVO). This was a prospective multicenter intervention study. We evaluated 50 eyes in 50 patients with ME due to BRVO enrolled between October 2016 and September 2017. The patients received intravitreal aflibercept (IVA) injections according to a mTAE regimen for 24 months. This study reports the secondary endpoints of best-corrected visual acuity (BCVA) and central subfield thickness (CST) at 24 months and compares them with previously reported primary endpoints. Compared with baseline BCVA and CST of 0.33 (0.27) and 488 (165) µm (mean (standard deviation)), respectively, BCVA and CST were significantly improved at 12 and 24 months (12 months: 0.059 (0.19) LogMAR and 299 (112) µm; 24 months: 0.034 (0.18) LogMAR and 272 (81) µm, respectively; both p < 0.0001). Over the 24-month period, the mean number of IVA injections and clinic visits was 7.4 (3.3) and 11.1 (2.0), respectively. The mTAE regimen of IVA injections for ME due to BRVO was effective for improving BCVA and reducing CST over 24 months. This regimen shows promise for reducing the number of injections and clinic visits. MDPI 2021-07-17 /pmc/articles/PMC8307685/ /pubmed/34300328 http://dx.doi.org/10.3390/jcm10143162 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Arai, Yusuke Takahashi, Hidenori Inoda, Satoru Sakamoto, Shinichi Tan, Xue Inoue, Yuji Tominaga, Satoko Kawashima, Hidetoshi Yanagi, Yasuo Efficacy of Modified Treat-and-Extend Regimen of Aflibercept for Macular Edema from Branch Retinal Vein Occlusion: 2-Year Prospective Study Outcomes |
title | Efficacy of Modified Treat-and-Extend Regimen of Aflibercept for Macular Edema from Branch Retinal Vein Occlusion: 2-Year Prospective Study Outcomes |
title_full | Efficacy of Modified Treat-and-Extend Regimen of Aflibercept for Macular Edema from Branch Retinal Vein Occlusion: 2-Year Prospective Study Outcomes |
title_fullStr | Efficacy of Modified Treat-and-Extend Regimen of Aflibercept for Macular Edema from Branch Retinal Vein Occlusion: 2-Year Prospective Study Outcomes |
title_full_unstemmed | Efficacy of Modified Treat-and-Extend Regimen of Aflibercept for Macular Edema from Branch Retinal Vein Occlusion: 2-Year Prospective Study Outcomes |
title_short | Efficacy of Modified Treat-and-Extend Regimen of Aflibercept for Macular Edema from Branch Retinal Vein Occlusion: 2-Year Prospective Study Outcomes |
title_sort | efficacy of modified treat-and-extend regimen of aflibercept for macular edema from branch retinal vein occlusion: 2-year prospective study outcomes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307685/ https://www.ncbi.nlm.nih.gov/pubmed/34300328 http://dx.doi.org/10.3390/jcm10143162 |
work_keys_str_mv | AT araiyusuke efficacyofmodifiedtreatandextendregimenofafliberceptformacularedemafrombranchretinalveinocclusion2yearprospectivestudyoutcomes AT takahashihidenori efficacyofmodifiedtreatandextendregimenofafliberceptformacularedemafrombranchretinalveinocclusion2yearprospectivestudyoutcomes AT inodasatoru efficacyofmodifiedtreatandextendregimenofafliberceptformacularedemafrombranchretinalveinocclusion2yearprospectivestudyoutcomes AT sakamotoshinichi efficacyofmodifiedtreatandextendregimenofafliberceptformacularedemafrombranchretinalveinocclusion2yearprospectivestudyoutcomes AT tanxue efficacyofmodifiedtreatandextendregimenofafliberceptformacularedemafrombranchretinalveinocclusion2yearprospectivestudyoutcomes AT inoueyuji efficacyofmodifiedtreatandextendregimenofafliberceptformacularedemafrombranchretinalveinocclusion2yearprospectivestudyoutcomes AT tominagasatoko efficacyofmodifiedtreatandextendregimenofafliberceptformacularedemafrombranchretinalveinocclusion2yearprospectivestudyoutcomes AT kawashimahidetoshi efficacyofmodifiedtreatandextendregimenofafliberceptformacularedemafrombranchretinalveinocclusion2yearprospectivestudyoutcomes AT yanagiyasuo efficacyofmodifiedtreatandextendregimenofafliberceptformacularedemafrombranchretinalveinocclusion2yearprospectivestudyoutcomes |